T1	CHEM 4 12	nicotina
#1	AnnotatorNotes T1	C0028040; nicotine; Organic Chemical · Hazardous or Poisonous Substance
T2	PROC 1438 1442	iPTH
T3	PROC 28 42	fosfato sérico
#2	AnnotatorNotes T3	C0036820; Serum Phosphate Test; Laboratory Procedure
T4	PROC 55 58	HDL
#3	AnnotatorNotes T4	C0392885; High density lipoprotein measurement; Laboratory Procedure
T5	DISO 68 83	trombocitopenia
#4	AnnotatorNotes T5	C0040034; Thrombocytopenia; Disease or Syndrome
T6	PROC 100 112	hemodiálisis
#5	AnnotatorNotes T6	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T7	CHEM 211 223	nicotinamida
#6	AnnotatorNotes T7	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T8	CHEM 235 242	fármaco
#7	AnnotatorNotes T8	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T9	DISO 258 273	hiperfosfatemia
#8	AnnotatorNotes T9	C0085681; Hyperphosphatemia (disorder); Disease or Syndrome
T10	PROC 290 302	hemodiálisis
#9	AnnotatorNotes T10	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T11	PROC 316 352	evaluaron la eficacia y la seguridad
#10	AnnotatorNotes T11	C0511730; Identify product efficacy and safety issues; Health Care Activity
T12	CHEM 359 371	nicotinamida
#11	AnnotatorNotes T12	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T13	CHEM 491 498	fósforo
#12	AnnotatorNotes T13	C0031705; phosphorus; Element, Ion, or Isotope
T14	ANAT 499 505	sérico
#13	AnnotatorNotes T14	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T15	PROC 547 572	estudio clínico aleatorio
#14	AnnotatorNotes T15	C0206034; Clinical Trials, Randomized; Research Activity
T16	CHEM 657 669	nicotinamida
#15	AnnotatorNotes T16	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T17	PROC 681 688	placebo
#16	AnnotatorNotes T17	C0032042; Placebos; Therapeutic or Preventive Procedure
T18	CHEM 775 787	nicotinamida
#17	AnnotatorNotes T18	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T19	ANAT 892 898	sangre
#18	AnnotatorNotes T19	C0005767; Blood; Body Substance
T20	CHEM 970 982	nicotinamida
#19	AnnotatorNotes T20	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T21	CHEM 996 1003	fósforo
#20	AnnotatorNotes T21	C0031705; phosphorus; Element, Ion, or Isotope
T22	CHEM 1245 1248	HDL
#21	AnnotatorNotes T22	C0023821; High Density Lipoproteins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T23	CHEM 1399 1405	calcio
#22	AnnotatorNotes T23	C0006675; calcium; Pharmacologic Substance · Biologically Active Substance · Element, Ion, or Isotope
T24	ANAT 1406 1412	sérico
#23	AnnotatorNotes T24	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T25	PROC 1414 1425	ácido úrico
#24	AnnotatorNotes T25	C0202239; Uric acid measurement (procedure); Laboratory Procedure
T26	PROC 1427 1430	TGO
#25	AnnotatorNotes T26	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T27	ANAT 1532 1541	plaquetas
#26	AnnotatorNotes T27	C0005821; Blood Platelets; Cell
T28	PROC 1634 1641	placebo
#27	AnnotatorNotes T28	C0032042; Placebos; Therapeutic or Preventive Procedure
T29	CHEM 1684 1696	nicotinamida
#28	AnnotatorNotes T29	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T30	PROC 1728 1735	fósforo
#29	AnnotatorNotes T30	C0202178; Phosphorus measurement; Laboratory Procedure
T31	PROC 1748 1751	HDL
#30	AnnotatorNotes T31	C0392885; High density lipoprotein measurement; Laboratory Procedure
T32	DISO 1761 1776	trombocitopenia
#31	AnnotatorNotes T32	C0040034; Thrombocytopenia; Disease or Syndrome
T33	CHEM 1786 1798	nicotinamida
#32	AnnotatorNotes T33	C0028027; niacinamide; Organic Chemical · Pharmacologic Substance · Vitamin
T34	PROC 1809 1830	recuento de plaquetas
#33	AnnotatorNotes T34	C0032181; Platelet Count measurement; Laboratory Procedure
T35	ANAT 1821 1830	plaquetas
#34	AnnotatorNotes T35	C0005821; Blood Platelets; Cell
T36	DISO 1839 1854	trombocitopenia
#35	AnnotatorNotes T36	C0040034; Thrombocytopenia; Disease or Syndrome
T37	PROC 1959 1979	evaluar la seguridad
#36	AnnotatorNotes T37	C1705187; Safety Study; Research Activity
T38	CHEM 1984 1991	fármaco
#37	AnnotatorNotes T38	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T39	CHEM 28 35	fosfato
#38	AnnotatorNotes T39	C1601799; phosphate ion; Element, Ion, or Isotope · Pharmacologic Substance
T40	ANAT 36 42	sérico
#39	AnnotatorNotes T40	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T41	PROC 117 158	ensayo clínico aleatorizado a doble ciego
#40	AnnotatorNotes T41	C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity
T42	PROC 491 505	fósforo sérico
#41	AnnotatorNotes T42	C2229833; serum phosphorus measurement; Laboratory Procedure
T43	PROC 582 599	asignados al azar
#42	AnnotatorNotes T43	C0034656; Randomization; Research Activity
T44	PROC 880 898	muestras de sangre
#43	AnnotatorNotes T44	C0005834; Collection of blood specimen for laboratory procedure; Diagnostic Procedure | C1277698; Blood sample taken; Laboratory Procedure
T45	PROC 987 1003	nivel de fósforo
#44	AnnotatorNotes T45	C2229833; serum phosphorus measurement; Laboratory Procedure
T46	PROC 1138 1161	producto calcio-fósforo
#45	AnnotatorNotes T46	C3641229; Calcium and Phosphorus Product Measurement; Laboratory Procedure
T47	PROC 1224 1231	fósforo
#46	AnnotatorNotes T47	C0202178; Phosphorus measurement; Laboratory Procedure
T48	PROC 1236 1248	nivel de HDL
#47	AnnotatorNotes T48	C0392885; High density lipoprotein measurement; Laboratory Procedure
T49	PROC 1388 1412	niveles de calcio sérico
#48	AnnotatorNotes T49	C0728876; Serum calcium measurement; Laboratory Procedure
T50	PROC 1432 1435	TGP
#49	AnnotatorNotes T50	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T51	PROC 1520 1541	recuento de plaquetas
#50	AnnotatorNotes T51	C0032181; Platelet Count measurement; Laboratory Procedure
T52	Route 13 17	oral
#51	AnnotatorNotes T52	C1527415; Oral Route of Drug administration; Functional Concept
T53	LIVB 87 96	pacientes
#52	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Date 174 187	Recientemente
T56	LIVB 277 286	pacientes
#53	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 381 390	pacientes
#54	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	LIVB 477 486	pacientes
#55	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T60	Duration 706 715	8 semanas
T61	Duration 720 742	las primeras 4 semanas
T62	Dose 765 771	500 mg
T63	Frequency 788 794	al día
T64	Duration 823 832	4 semanas
T65	Dose 855 863	1.000 mg
T66	Frequency 863 867	/día
T69	Duration 1051 1067	la quinta semana
T71	Duration 1105 1121	la novena semana
T73	Duration 1298 1314	la quinta semana
T75	Duration 1354 1370	la novena semana
T77	Duration 1498 1515	la primera semana
T78	Duration 1545 1570	la quinta y novena semana
T80	LIVB 1670 1679	pacientes
#56	AnnotatorNotes T80	C0030705; Patients; Patient or Disabled Group
T81	LIVB 1906 1915	pacientes
#57	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T82	LIVB 2021 2032	poblaciones
#58	AnnotatorNotes T82	C1257890; Population; Population Group
T55	PROC 833 852	se aumentó la dosis
#59	AnnotatorNotes T55	C1707810; Dose Increased; Therapeutic or Preventive Procedure
T59	Duration 902 937	la primera, quinta y novena semanas
T67	Neg_cue 1443 1445	no
T68	CONC 1446 1453	cambian
A1	Assertion T68 Negated
#60	AnnotatorNotes T68	C0392747; Changing; Functional Concept | C0443172; Changed status; Quantitative Concept
R1	Negation Arg1:T67 Arg2:T68	
T70	Neg_cue 1582 1584	No
T72	CONC 1599 1606	cambios
A2	Assertion T72 Negated
#61	AnnotatorNotes T72	C0443172; Changed status; Quantitative Concept
R2	Negation Arg1:T70 Arg2:T72	
T74	Spec_cue 195 203	sugerido
T76	Quantifier_or_Qualifier 243 249	eficaz
A3	Assertion T76 Speculated
#62	AnnotatorNotes T76	C1704419; Effective; Qualitative Concept
A4	Assertion T8 Speculated
R3	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T76	
R4	Speculation Arg1:T74 Arg2:T8	
R5	Speculation Arg1:T74 Arg2:T76	
R6	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T76	
A5	Assertion T7 Speculated
R7	Speculation Arg1:T74 Arg2:T7	
R8	Has_Route_or_Mode Arg1:T1 Arg2:T52	
R9	Location_of Arg1:T40 Arg2:T3	
R10	Experiences Arg1:T53 Arg2:T6	
R11	Experiences Arg1:T53 Arg2:T5	
R12	Experiences Arg1:T53 Arg2:T4	
R13	Experiences Arg1:T53 Arg2:T3	
R14	Experiences Arg1:T53 Arg2:T1	
T79	Observation 18 42	reduce el fosfato sérico
#63	AnnotatorNotes T79	C0858891; Serum inorganic phosphate decreased; Finding (?)
R15	Causes Arg1:T1 Arg2:T79	
T83	Observation 44 58	aumenta el HDL
#64	AnnotatorNotes T83	C0853084; High density lipoprotein increased; Finding
R16	Location_of Arg1:T40 Arg2:T79	
R17	Experiences Arg1:T53 Arg2:T83	
R18	Experiences Arg1:T53 Arg2:T79	
R19	Experiences Arg1:T56 Arg2:T9	
R20	Experiences Arg1:T56 Arg2:T7	
R21	Experiences Arg1:T56 Arg2:T8	
R22	Experiences Arg1:T56 Arg2:T10	
R23	Overlap Arg1:T7 Arg2:T54	
R24	Overlap Arg1:T8 Arg2:T54	
R25	Experiences Arg1:T57 Arg2:T12	
R26	Location_of Arg1:T14 Arg2:T42	
R27	Experiences Arg1:T58 Arg2:T42	
T84	Observation 506 515	en ayunas
#65	AnnotatorNotes T84	C0015663; Fasting; Finding
R28	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T84	
R29	Experiences Arg1:T58 Arg2:T16	
R30	Before Arg1:T42 Arg2:T16	
R31	Before Arg1:T42 Arg2:T17	
R32	Before Arg1:T43 Arg2:T16	
R33	Before Arg1:T43 Arg2:T17	
T85	PROC 693 700	estudio
#66	AnnotatorNotes T85	C0681814; research study; Research Activity
R34	Has_Duration_or_Interval Arg1:T85 Arg2:T60	
R35	Has_Duration_or_Interval Arg1:T18 Arg2:T61	
R36	Has_Dose_or_Strength Arg1:T18 Arg2:T62	
R37	Has_Frequency Arg1:T18 Arg2:T63	
R38	Has_Duration_or_Interval Arg1:T55 Arg2:T64	
R39	Before Arg1:T18 Arg2:T55	
R41	Has_Dose_or_Strength Arg1:T18 Arg2:T65	
R40	Has_Frequency Arg1:T18 Arg2:T66	
R43	Overlap Arg1:T44 Arg2:T59	
T86	Observation 987 1013	nivel de fósforo se redujo
#67	AnnotatorNotes T86	C0858891; Serum inorganic phosphate decreased; Finding (?)
R44	Causes Arg1:T20 Arg2:T86	
R45	Overlap Arg1:T45 Arg2:T69	
R46	Overlap Arg1:T86 Arg2:T69	
R47	Overlap Arg1:T86 Arg2:T71	
R48	Overlap Arg1:T45 Arg2:T71	
T87	Observation 1138 1171	producto calcio-fósforo se redujo
T88	Observation 1236 1256	nivel de HDL aumentó
#68	AnnotatorNotes T88	C0853084; High density lipoprotein increased; Finding
R49	Overlap Arg1:T48 Arg2:T73	
R50	Overlap Arg1:T88 Arg2:T73	
R51	Overlap Arg1:T88 Arg2:T75	
R52	Overlap Arg1:T48 Arg2:T75	
R53	Location_of Arg1:T24 Arg2:T49	
R54	Overlap Arg1:T51 Arg2:T77	
R55	Overlap Arg1:T51 Arg2:T78	
T89	Observation 1520 1541;1571 1580	recuento de plaquetas disminuyó
#69	AnnotatorNotes T89	C0392386; Decreased platelet count; Finding
R58	Experiences Arg1:T80 Arg2:T29	
R59	Experiences Arg1:T80 Arg2:T30	
R60	Experiences Arg1:T80 Arg2:T32	
R61	Causes Arg1:T29 Arg2:T32	
R62	Causes Arg1:T1 Arg2:T5	
T90	Observation 1799 1830	redujo el recuento de plaquetas
#70	AnnotatorNotes T90	C0392386; Decreased platelet count; Finding
R63	Causes Arg1:T33 Arg2:T90	
T91	Observation 1737 1751	aumentó el HDL
#71	AnnotatorNotes T91	C0853084; High density lipoprotein increased; Finding
R64	Causes Arg1:T29 Arg2:T91	
T92	Observation 1697 1706;1725 1735	disminuyó el fósforo
R65	Experiences Arg1:T80 Arg2:T92	
R66	Causes Arg1:T29 Arg2:T92	
R67	Experiences Arg1:T80 Arg2:T91	
R68	Experiences Arg1:T80 Arg2:T31	
R69	Causes Arg1:T33 Arg2:T36	
R70	Experiences Arg1:T81 Arg2:T33	
R71	Experiences Arg1:T81 Arg2:T90	
R72	Experiences Arg1:T81 Arg2:T34	
R73	Experiences Arg1:T81 Arg2:T36	
R74	Experiences Arg1:T81 Arg2:T38	
T93	Quantifier_or_Qualifier 1454 1477	de manera significativa
A6	Assertion T93 Negated
#72	AnnotatorNotes T93	C0750502; Significant; Idea or Concept
R42	Has_Quantifier_or_Qualifier Arg1:T68 Arg2:T93	
R75	Negation Arg1:T67 Arg2:T93	
T94	Quantifier_or_Qualifier 1607 1621	significativos
A7	Assertion T94 Negated
#73	AnnotatorNotes T94	C0750502; Significant; Idea or Concept
R76	Has_Quantifier_or_Qualifier Arg1:T72 Arg2:T94	
T95	Result_or_Value 516 525	> 5 mg/dl
R77	Has_Result_or_Value Arg1:T42 Arg2:T95	
R78	Used_for Arg1:T18 Arg2:T55	
R79	Overlap Arg1:T89 Arg2:T77	
R56	Overlap Arg1:T89 Arg2:T78	
#74	AnnotatorNotes T92	C0858891; Serum inorganic phosphate decreased; Finding (?)
R57	Experiences Arg1:T82 Arg2:T33	
R80	Experiences Arg1:T82 Arg2:T90	
R81	Experiences Arg1:T82 Arg2:T34	
R82	Experiences Arg1:T82 Arg2:T36	
R83	Experiences Arg1:T82 Arg2:T38	
#75	AnnotatorNotes T54	C0332185; Recent; Temporal Concept
#76	AnnotatorNotes T2	C2697755; Intact Parathyroid Hormone Measurement; Laboratory Procedure
A8	Experiencer T53 Patient
A9	Experiencer T56 Patient
A10	Experiencer T57 Patient
A11	Experiencer T58 Patient
A12	Experiencer T80 Patient
A13	Experiencer T81 Patient
A14	Experiencer T82 Patient
R84	Has_Result_or_Value Arg1:T4 Arg2:T83	
R85	Has_Result_or_Value Arg1:T3 Arg2:T79	
R86	Has_Result_or_Value Arg1:T45 Arg2:T86	
R87	Has_Result_or_Value Arg1:T46 Arg2:T87	
R88	Has_Result_or_Value Arg1:T48 Arg2:T88	
R89	Has_Result_or_Value Arg1:T51 Arg2:T89	
R90	Has_Result_or_Value Arg1:T31 Arg2:T91	
R91	Has_Result_or_Value Arg1:T30 Arg2:T92	
R92	Has_Result_or_Value Arg1:T34 Arg2:T90	
